Postpartum Infection After an Unscheduled C-Section: What a New 2026 Study Found

Many of my birth injury clients ultimately deliver by emergency C-section.

So when I saw a new 2026 study looking at postpartum infection after unscheduled cesarean delivery, it caught my attention.

But to understand why this new study matters, you have to go back about ten years.

What Was the Standard Practice Before 2016?

Antibiotics before a C-section are not new.

Before 2016, patients undergoing cesarean delivery were already routinely given prophylactic antibiotics, commonly a cephalosporin such as cefazolin, before the skin incision to reduce the risk of postoperative infection.

But infection remained a significant concern, particularly for patients undergoing an unscheduled C-section during labor or after their membranes had ruptured.

That raised an important question: Could adding a second antibiotic provide additional protection for patients undergoing an unscheduled C-section?

What Changed in 2016?

In September 2016, researchers published a large randomized clinical trial involving 2,013 patients undergoing nonelective cesarean delivery during labor or after membrane rupture.

Importantly, everyone in the study was already scheduled to receive the standard antibiotic prophylaxis.

The researchers then randomized patients to receive either a placebo or an additional antibiotic, 500 mg of intravenous azithromycin.

The results were significant.

Postoperative infection occurred in:

  • 12.0% of patients who received standard antibiotic prophylaxis plus placebo
  • 6.1% of patients who received standard prophylaxis plus azithromycin

The study also found lower rates of both endometritis and wound infection in the azithromycin group.

In other words, the study was not showing that antibiotics before an unscheduled C-section were beneficial. That was already standard practice.

It showed that adding azithromycin to the existing antibiotic regimen substantially reduced postoperative infection in this higher-risk group.

Then ACOG Incorporated the Evidence

In 2018, the American College of Obstetricians and Gynecologists addressed the evidence in Practice Bulletin No. 199, Use of Prophylactic Antibiotics in Labor and Delivery.

ACOG stated that adjunctive azithromycin may be considered for patients undergoing an unscheduled cesarean delivery.

That distinction is important. Azithromycin was an adjunct to the standard prophylactic antibiotic regimen, not a replacement for it.

So by 2018, we had moved from a randomized clinical trial showing a substantial reduction in infection to professional guidance incorporating that evidence into clinical practice.

But that left another question:

What actually happened when that evidence moved from a clinical trial into hospitals across the country?

Ten Years Later, Researchers Looked at What Happened in Real-World Practice

That is where the new 2026 study comes in.

Researchers wanted to know whether the evidence from the 2016 trial had actually been adopted in clinical practice and what happened to postpartum infection rates as that adoption occurred.

They analyzed 1,663,441 births from 2013 through 2024, including more than 200,000 cesarean deliveries.

Before publication of the 2016 trial, azithromycin was documented in only 2.2% of cesarean births included in the study.

After publication, that increased to 39.6%.

During the same periods, postpartum infection among the cesarean group decreased from 9.2% to 8.0%.

The researchers also compared those trends with vaginal births. After adjustment, they found a 2.0 percentage-point decrease in postpartum infection among cesarean births relative to the change among vaginal births, which represented approximately a 20% relative decrease.

The researchers concluded that after publication of the 2016 trial, azithromycin use for patients undergoing unscheduled cesarean delivery increased and postpartum infection rates decreased in the United States.

Why the 2026 Study Is Different

The 2016 study asked:

Does adding azithromycin to standard antibiotic prophylaxis reduce infection after an unscheduled C-section?

The 2026 study asked something different:

Did that evidence actually make its way into clinical practice, and what happened to infection rates when it did?

That distinction matters.

A randomized clinical trial can tell us whether an intervention works under the conditions of the trial. But that does not necessarily tell us how widely the intervention will be adopted or what outcomes will look like when it is used across different hospitals and patient populations.

The 2026 study gives us a much larger, real-world look at what happened after the 2016 evidence was published.

It also does not prove that increased azithromycin use, by itself, caused the entire decline in postpartum infection. The study was observational, and other changes in clinical practice over that period could have contributed to the results.

But the researchers found that the increased use of azithromycin was associated with decreased postpartum infection in a large real-world population, supporting the findings of the original 2016 trial.

Why This Caught My Attention as a Birth Injury Lawyer

Many of my birth injury clients ultimately deliver by emergency C-section.

And when I review those cases, my review does not stop when the baby is delivered.

I am often reconstructing what happened during labor, what led to the decision to perform the C-section, and whether that decision was timely. But I am also looking at the mother’s postpartum course.

That includes questions like: What infection risks were present? What prophylactic antibiotics were administered and when? Were there signs of infection after delivery? How quickly were those signs recognized and treated? Did the mother require additional antibiotics, an emergency department visit, or readmission?

Importantly, developing an infection after an emergency C-section does not mean that medical negligence occurred. Infections can occur even when appropriate preventive measures and appropriate care are provided.

But when research identifies a known risk and evidence-based measures intended to reduce that risk, those are things I want to understand when I review the complete course of care.

And that is what makes this 2026 study particularly interesting to me. It is not announcing a brand-new intervention. It is looking back, ten years after an important clinical trial, to see how that evidence translated into actual clinical practice and what happened to patient outcomes.

Sources

  1. Freret TS, Litman E, Wen T, et al. Adoption of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postpartum Infections. JAMA. 2026;336(17):1539-1547. doi:10.1001/jama.2026.15010.
  2. Tita ATN, Szychowski JM, Boggess K, et al. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. New England Journal of Medicine. 2016;375:1231-1241. doi:10.1056/NEJMoa1602044.
  3. American College of Obstetricians and Gynecologists. Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics & Gynecology. 2018;132(3). Reaffirmed 2025.

Disclaimer

This article is for educational and informational purposes only and is not intended as medical or legal advice. Medical guidelines and standards of care may change over time and may vary depending on the individual patient’s clinical circumstances. The development of an infection or other complication following a cesarean delivery does not, by itself, establish that medical negligence occurred. Whether medical care met the applicable standard of care requires an evaluation of the specific facts and circumstances of an individual case.

Related Posts

Looking For Answers?
We Handle Personal Injury Cases

Contact us Now

What Our Clients Have To Say...